Patents Assigned to The United States of America, as represented by the Secretary, Department of Health and Human
  • Publication number: 20210292758
    Abstract: Methods are disclosed herein for treating glaucoma in a subject. In some embodiments, the methods increase retinal ganglion cell survival. The disclosed methods use exosomes and/or miRNA.
    Type: Application
    Filed: June 7, 2021
    Publication date: September 23, 2021
    Applicant: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Servic
    Inventors: Stanislav Ivanovich Tomarev, Benjamin Frank John Martin Mead
  • Publication number: 20210283240
    Abstract: Metapneumovirus (MPV) F proteins stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the MPV F proteins and/or nucleic acid molecules can be used to generate an immune response to MPV in a subject. In additional embodiments, the therapeutically effective amount of the MPV F ectodomain trimers and/or nucleic acid molecules can be administered to a subject in a method of treating or preventing MPV infection.
    Type: Application
    Filed: May 28, 2021
    Publication date: September 16, 2021
    Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Servic, Institute for Research in Biomedicine
    Inventors: Peter Kwong, Michael Gordon Joyce, Baoshan Zhang, Yongping Yang, Peter Collins, Ursula Buchholz, Davide Corti, Antonio Lanzavecchia, Guillaume Stewart-Jones
  • Patent number: 11116830
    Abstract: Immunogenic compositions that include a bacterial capsular polysaccharide conjugated to a carrier protein are described. In some embodiments, the bacterial capsular polysaccharide is a Neisseria meningitidis capsular polysaccharide. The carrier protein includes an N. meningitidis factor H binding protein (fHbp) linked to cholera toxin subunit B (CTB). Administration of the immunogenic compositions elicits an immune response that includes production of meningococcal polysaccharide-specific and fHbp-specific antibodies. Use of the immunogenic compositions as meningococcal vaccines is also described.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: September 14, 2021
    Assignee: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services
    Inventors: Gregory A. Price, Che-Hung Robert Lee, Margaret C. Bash
  • Publication number: 20210275664
    Abstract: Coronavirus S ectodomain trimers stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the coronavirus S ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to coronavirus in a subject. In additional embodiments, the therapeutically effective amount of the coronavirus S ectodomain trimers and/or nucleic acid molecules can be administered to a subject in a method of treating or preventing coronavirus infection.
    Type: Application
    Filed: March 8, 2021
    Publication date: September 9, 2021
    Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Servic, The Scripps Research Institute, Trustees of Dartmouth College
    Inventors: Barney Graham, Jason McLellan, Andrew Ward, Robert Kirchdoerfer, Christopher Cottrell, Michael Gordon Joyce, Masaru Kanekiyo, Nianshuang Wang, Jesper Pallesen, Hadi Yassine, Hannah Turner, Kizzmekia Corbett
  • Publication number: 20210278328
    Abstract: The present disclosure provides various embodiments of a fluorescence scanning system having a sample holder with a sample suspended within that is rotated by a centrifuge such that the sample is illuminated at various angles by an excitation beam by operation of a galvanometer and such that the sample emits a fluorescence emissions that is detected through a narrow window of exposure defined along the travel path of rotation taken by the sample holder when rotated by the centrifuge. A stationary fluorescence detector is in operative communication with the sample holder along the narrow window of exposure for detecting the fluorescence emissions emitted by the sample from the sample holder while also separating the excitation beam from the fluorescence emissions.
    Type: Application
    Filed: March 4, 2021
    Publication date: September 9, 2021
    Applicant: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Servic
    Inventors: Peter W. Schuck, John W. Kakareka, Thomas J. Pohida, George Patterson, Hauying Zhao
  • Patent number: 11110089
    Abstract: There is provided compounds of formula (I) or pharmaceutically-acceptable salts thereof, wherein W, X, Y, Z, R1, R2 and R3 have meanings provided in the description, which compounds are useful in the treatment of cancers.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: September 7, 2021
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Elias Set Jenö Arnér
    Inventors: Elias Set Jenö Arnér, William Chester Stafford, Nathan Patrick Coussens, Diane Karen Luci, David Joseph Maloney, Anton Simeonov, Ajit Jadhav, Thomas S. Dexheimer
  • Patent number: 11110181
    Abstract: The present disclosure is directed to methods and compositions for the diagnosis and/or treatment of tumors, such as ocular tumors, using virus-like particles conjugated to photosensitive molecules.
    Type: Grant
    Filed: January 31, 2020
    Date of Patent: September 7, 2021
    Assignees: Aura Biosciences, Inc., The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Elisabet de los Pinos, John Todd Schiller, Rhonda C. Kines, John MacDougall
  • Patent number: 11111478
    Abstract: Provided are methods of producing an isolated T memory stem cell population, the method comprising a) isolating naïve T cells from a mammal, wherein the mammal is not a mouse; b) activating the naïve T cells and expanding the numbers of naïve T cells in the presence of one or more non-specific T cell stimuli, one or more cytokines, and a GSK-3beta inhibitor. Also provided are methods of producing an isolated T memory stem cell population, the method comprising a) isolating lymphocytes from a mammal; b) sorting the lymphocytes using flow cytometry into a population comprising a phenotype comprising i) CD95+, CD45RO?, and CCR7+; and ii) CD62L+ or one or more of CD27+, CD28+, CD45RA+, and CD127+ to produce an isolated T memory stem cell population. Further embodiments of the invention provide related cells, populations of cells, pharmaceutical compositions, and methods of treating or preventing cancer.
    Type: Grant
    Filed: May 13, 2019
    Date of Patent: September 7, 2021
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Luca Gattinoni, Enrico Lugli, Mario Roederer, Nicholas P. Restifo
  • Patent number: 11111306
    Abstract: Antibodies and antigen binding fragments that specifically bind to IL-7R? are disclosed. Nucleic acids encoding the antibodies and antigen binding fragments, and vectors including the nucleic acid molecules are also provided. Methods for detecting a ca cancer or a cell that expresses IL-7R? using the antibodies and antigen binding fragments are disclosed, as is the use of the antibodies and antigen binding fragments to prevent and/or treat a subject with a cancer that expresses IL-7R?, such as acute lymphoblastic leukemia.
    Type: Grant
    Filed: July 1, 2019
    Date of Patent: September 7, 2021
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, University of Maryland, College Park
    Inventors: Scott Durum, Julie Hixon, Wen Qing Li, Scott Walsh, Lila Kashi
  • Patent number: 11110150
    Abstract: The present invention relates to agents that modulate interleukin-15 (“IL-15”) signal transduction or function (“Therapeutic Agents”) and the use ol” those agents to modulate immune function. The Therapeutic Agents target the interaction between IL-15 and its receptor and modulate IL-15-induced signal transduction. The Therapeutic Agents may be formulated with polymers, such as poly-?-1-?4-N-acetylglucosamine. for administration to a human subject to modulate IL-15-mediated immune function.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: September 7, 2021
    Assignees: NOVARTIS AG, The United States of America, as Represented by the Secretary, Department of Health and Human Services
    Inventors: Barbara K. Felber, Sergio Finkielsztein, George N. Pavlakis, John V. Vournakis
  • Patent number: 11112472
    Abstract: A gradient system characterization function (e.g., a gradient system transfer function) may be developed by measuring a behavior of the MR device at a target temperature and developing at least one gradient system characterization function for a gradient coil of a magnetic resonance (MR) device at the target temperature based on the measured behavior. A patient may be subsequently imaged by the MR device, wherein the imaging process comprises measuring a temperature of a gradient coil, determining a gradient system characterization function at the measured temperature, calculating a pre-emphasized gradient of the gradient coil, and imaging the patient using the pre-emphasized magnetic field component.
    Type: Grant
    Filed: November 29, 2019
    Date of Patent: September 7, 2021
    Assignees: Siemens Healthcare GmbH, Julius-Maximilians-Universität Würzburg, THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services
    Inventors: Gudrun Ruyters, Andrew Dewdney, Manuel Stich, Herbert Köstler, Christiane Pfaff, Tobias Wech, Adrienne Campbell
  • Patent number: 11103572
    Abstract: Methods of thermally inactivating a rotavirus are provided according to the present invention which include exposing the rotavirus to a temperature in the range of about 50° C.-80° C., inclusive, for an incubation time sufficient to render the rotavirus incapable of replication or infection. The thermally inactivated rotavirus is antigenic and retains a substantially intact rotavirus particle structure. Vaccine compositions and methods of vaccinating a subject against rotavirus are provided which include generation and use of thermally inactivated rotavirus.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: August 31, 2021
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Baoming Jiang, Roger I. Glass, Jean-Francois Saluzzo
  • Patent number: 11106027
    Abstract: A resolution enhancement technique for a line scanning confocal microscopy system that generates vertical and horizontal line scanning patterns onto a sample is disclosed. The line scanning confocal microscopy system is capable of producing line scanning patterns through the use of two alternative pathways that generate either the vertical line scanning pattern or horizontal line scanning pattern.
    Type: Grant
    Filed: April 1, 2019
    Date of Patent: August 31, 2021
    Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Hari Shroff, Andrew York, John Giannini, Abhishek Kumar
  • Publication number: 20210263054
    Abstract: A method and treatment for testing efficiency and effectiveness of a near infrared photoimmunotherapy treatment includes injecting an antibody photosensitizer conjugate (APC) into a patient, applying radiation to the patient, thereby causing the APC to release a ligand, which is excreted in the patients urine, detecting the presence of the ligand with liquid chromatography-mass spectrometry, measuring and quantifying an amount of the ligand present in the patients urine based on analytical results of the liquid chromatography-mass spectrometry, and determining the effectiveness of the near infrared photo-immunotherapy treatment based on the measured quantified amount of the ligand present in the patients urine so as to determine an amount of APC remaining in the patient.
    Type: Application
    Filed: June 20, 2019
    Publication date: August 26, 2021
    Applicants: SHIMADZU CORPORATION, THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC
    Inventors: Hisataka KOBAYASHI, Masayuki NISHIMURA
  • Publication number: 20210263170
    Abstract: Methods and apparatus for calibrating radioactive sources are described. An array of scintillation detectors form a receptacle within which a sample or sample container can be retained by a holder. The scintillation detectors are coupled via light transducers such as photomultiplier tubes (PMTs) to independent electronic counters. Coincidence processing of time-tagged events yields a correlated cent rate. One or more corrections can be applied as needed, for background counts, deadtime, or random coincidences. Voltage tuning of PMTs yields improved reproducibility. Variations are disclosed. 1% accuracy has been demonstrated over a range N of 10 kBq-3 MBq, covering a gap in the capabilities of conventional technology.
    Type: Application
    Filed: May 7, 2021
    Publication date: August 26, 2021
    Applicant: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC
    Inventor: Stephen S. Adler
  • Publication number: 20210260125
    Abstract: Provided are chimeric antigen receptors (CARs) having antigenic specificity for B-cell Maturation Antigen (SLAMF7). Also provided are related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the CARs. Methods of treating or preventing cancer in a mammal are also provided.
    Type: Application
    Filed: June 26, 2019
    Publication date: August 26, 2021
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: James N. Kochenderfer, Steven A. Feldman
  • Publication number: 20210261516
    Abstract: Methods for treating a tumor, such as a benign or malignant tumor, are disclosed herein. The methods include administering a therapeutically effective amount of a small molecule that selectively binds to and stabilizes G-quadruplex DNA in the promoter of the c-MYC gene to the subject. The methods are also of use to decrease the size and/or number of metastases. Compounds for use in the disclosed methods are also provided.
    Type: Application
    Filed: May 3, 2021
    Publication date: August 26, 2021
    Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Servic, Yale University
    Inventors: John Schneekloth, JR., John Simmons, Kenneth Felsenstein, Beverly Mock, Lindsey Saunders, Peter Gareiss, David Calabrese, Elena Leon
  • Patent number: 11098283
    Abstract: Provided is an isolated or purified T cell comprising an antigen-specific receptor, wherein the antigen-specific receptor is a T cell receptor (TCR) or a chimeric antigen receptor (CAR), wherein the T cell has been modified to express a transcription factor at a level that is higher than the level of the transcription factor expressed by a T cell that has not been modified to express the transcription factor, wherein the transcription factor is V-Myb Avian Myeloblastosis Viral Oncogene Homolog (c-Myb), a functional variant of c-Myb, or a functional fragment of c-Myb. Related populations of cells, pharmaceutical compositions, methods of treating a disease, and methods of inhibiting the differentiation of T cells are also provided.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: August 24, 2021
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Sanjivan Gautam, Yun Ji, Luca Gattinoni
  • Patent number: 11098054
    Abstract: Disclosed is a compound of formula (I) in which a, R1-R5 and X1 are as described herein. Also disclosed are a pharmaceutical composition containing the compound and a method of using the compound for treating cancer, such as renal cancer.
    Type: Grant
    Filed: July 5, 2018
    Date of Patent: August 24, 2021
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Sciences, Fundacio Institut Catala D'Investigacio Quimica, University of Delaware, University of Leeds, Universitat Rovira I Virgili
    Inventors: John A. Beutler, Antonio Echavarren, William Chain, David Beech, Zhenhua Wu, Jean-Simon Suppo, Fernando Bravo, Hussein Rubaiy
  • Patent number: 11098084
    Abstract: The invention features modified alphavirus or flavivirus virus-like particles (VLPs). The invention provides methods, compositions, and kits featuring the modified VLPs. The invention also features methods for enhancing production of modified VLPs for use in the prevention or treatment of alphavirus and flavivirus-mediated diseases. The invention also provides methods for delivering agents to a cell using the modified VLPs.
    Type: Grant
    Filed: November 26, 2018
    Date of Patent: August 24, 2021
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Gary J. Nabel, Srinivas Rao, Wataru Akahata